Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia
(CML) are: avoid progression to accelerated phase or blast crisis CML such that patients …

Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase
chronic myeloid leukemia (CML-CP) who received≥ 2 prior tyrosine kinase inhibitors or …

Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of
care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and …

Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …

Objectives: Newer tyrosine kinase inhibitors (TKIs)(bosutinib, ponatinib) and allogeneic
hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in …

Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Introduction Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are
resistant or intolerant to second-generation tyrosine kinase inhibitors (TKIs) may benefit from …

Some species of clover are reported to have beneficial effects in human diseases. However,
little is known about the activity of the forage plant Trifolium repens, or white clover, which …

Background Imatinib mesylate (IM) is a first-line treatment option for patients with chronic
myeloid leukemia (CML). Patients who fail or are intolerant to IM therapy are treated with …